Employee Benefits

3 Months Ended

Mar. 31, 2020

NOTE 12 - EMPLOYEE BENEFITS

Healthcare

We participate in multiple healthcare plans, of which our primary plan is partially self-funded with an insurance company payment benefits in excess of stop loss limits per individual. Our healthcare benefit expense (net of employee contributions) was approximately $7.0 million and $4.8 million for the three months ended March 31,

2020 and 2019, respectively, for all plans. An accrual for estimated healthcare claims incurred but not reported (“IBNR”) is included within accrued compensation on the Condensed Consolidated Balance Sheets and was $2.9 million and $2.6 million as of March 31, 2020 and December 31, 2019, respectively.

Workers’ Compensation

Workers’ compensation expense totaled $4.4 million and $4.2 million for the three months ended March 31, 2020 and 2019, respectively. Workers’ compensation known claims and IBNR reserves included on the Condensed Consolidated Balance Sheets were as follows (in thousands):


	March 31, 2020		December 31, 2019
Included in other current liabilities	$	6,063	$	6,777
Included in other long-term liabilities		12,165		10,874

	$	18,228	$	17,651

We also had an insurance receivable for claims that exceeded the stop loss limit for fully insured policies included on the Condensed Consolidated Balance Sheets. This receivable offsets an equal liability included within the reserve amounts noted above and was as follows (in thousands):


	March 31, 2020		December 31, 2019
Included in other non-current assets	$	1,955	$	2,098

Retirement Plans

We participate in multiple 401(k) plans, whereby we provide a matching contribution of wages deferred by employees and can also make discretionary contributions to each plan. Certain plans allow for discretionary employer contributions only. These plans cover substantially all our eligible employees. We recognized 401(k) plan expenses of $0.6 million during each of the three months ended March 31, 2020 and 2019, respectively. These expenses are included in administrative expenses on the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income.

Share-Based Compensation

Common Stock Awards

We periodically grant shares of our common stock to

non-employee

members of our board of directors and our employees. During the three months ended March 31, 2020, we granted 316 shares of our common stock under our 2014 Omnibus Incentive Plan to a

non-employee

member of our board of directors. The stock will vest on the date of our 202

annual meeting. Accordingly, we recorded $33 thousand in compensation expense during the three months ended March 31, 2020. We did not grant any such shares during the three months ended March 31, 2019, however, we recorded $0.1 million in compensation expense during the three months ended March 31, 2019 related to prior grants to

non-employee

members of our board of directors. During the three months ended March 31, 2020 and 2019, we granted approximately seven and 11 thousand shares of our common stock, respectively, to employees and recorded $1.0 million and $1.1 million, respectively, of compensation expense associated with

non-performance-based

awards issued to employees.

As of March 31, 2020, we had $4.3 million of unrecognized compensation expense related to these nonvested common stock awards issued to

non-employee

members of our board of directors and our employees. This expense is subject to future adjustments for forfeitures and is expected to be recognized on a straight-line basis over the remaining weighted-average period of 1.8 years. Shares forfeited are returned as treasury shares and available for future issuances. See the table below for changes in shares and related weighted average

grant

ate

fair value

per share.

Employees – Performance-Based Stock Awards

During the three months ended March 31, 2020, we issued under our 2014 Omnibus Incentive Plan approximately 0.1 million shares of our common stock to certain officers, which vest in two equal installments on each of April 20, 2021 and April 20, 2022. In addition, during the three months ended March 31, 2020, we established, and our Board of Directors approved, performance-based targets in connection with common stock awards to be issued to certain officers in 2021 contingent upon achievement of these targets. Share-based compensation expense associated with these performance-based awards and prior performance-based grants was $1.0 million and $0.7 million for the three months ended March 31, 2020 and 2019, respectively.

As of March 31, 2020, we had $6.9 million of unrecognized compensation expense related to nonvested performance-based common stock awards. This expense is subject to future adjustments for forfeitures and is expected to be recognized over the remaining weighted-average period of 2.1 years using the graded-vesting method. See the table below for changes in shares and related weighted average

grant date

fair value per share.

Employees – Performance-Based Restricted Stock Units

During 2019, we established, and our board of directors approved, performance-based restricted stock units in connection with common stock awards to be issued to certain employees in 2020 based upon achievement of a performance target. These units will be accounted for as equity-based awards that will be settled with a fixed number of common shares. We recorded $0.2 million and $0.1 million in compensation expense associated with these performance-based units during the three months ended March 31, 2020 and 2019, respectively.

As of March 31, 2020, we had $33 thousand of unrecognized compensation expense related to nonvested performance-based common stock units. This expense is subject to future adjustments for forfeitures and is expected to be recognized on a straight-line basis over the remaining weighted-average period of 0.1 years. See the table below for changes in shares and related weighted average

grant

ate

fair value per share.

Share-Based Compensation Summary

Amounts and changes for each category of equity-based award were as follows:


	Common Stock Awards					Performance-Based Stock Awards				Performance-Based Restricted Stock Units
	Awards			Weighted Average Grant Date Fair Value Per Share		Awards		Weighted Average Grant Date Fair Value Per Share		Units			Weighted Average Grant Date Fair Value Per Share
Nonvested awards/units at December 31, 2019		152,882		$	52.93		160,289	$	50.49		13,186		$	51.62
Granted		7,420			75.88		57,450		77.28		—			—
Vested		(568	)		52.63		—		—		—			—
Forfeited/Cancelled		(1,759	)		52.25		—		—		(92	)		51.62

Nonvested awards/units at March 31, 2020		157,975		$	54.02		217,739	$	57.53		13,094		$	51.62

We recorded the following stock compensation expense by income statement category (in thousands):


	Three months ended March 31,
	2020		2019
Cost of sales	$	96	$	78
Selling		49		44
Administrative		2,536		1,816

	$	2,681	$	1,938

Administrative stock compensation expense includes all stock compensation earned by our administrative personnel, while cost of sales and selling stock compensation represents all stock compensation earned by our installation and sales employees, respectively. The difference between the sum of the expenses described above and the amount in the table is comprised primarily of expenses associated with immaterial liability-based awards.

As of March 31, 2020, approximately 2.1 million of the 3.0 million shares of common stock authorized for issuance were available for issuance under the 2014 Omnibus Incentive Plan.